The rise of theranostics: Part 1 -- Gaining momentum
AuntMinnie
MARCH 26, 2024
Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Traditional treatments didn't slow the disease in these patients, noted UT’s Vroman. please insert video here.
Let's personalize your content